A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Trial Profile

A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Poly ICLC (Primary) ; Cancer vaccine NY-ESO-1; Keyhole limpet haemocyanin; Melanoma vaccine MART-1; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Feb 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.
    • 10 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top